When considering the use of machine learning as a prognostic tool for patient survival—especially based on clinical parameters like treatment regimen, MGMT methylation status, and the inclusion of patients with tumor progression or recurrences—the development and implementation of an effective machine learning model remains a significant challenge [20, 33]. Here, MGMT is linked to neoplasm.